Johnson & Johnson to buy Swiss biotech company Actelion in a $30 billion all-cash deal

News Hour:

U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said on Thursday.

The biggest European drugs takeover in 13 years gives J&J access to the Swiss group’s range of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as its biggest product, Remicade for arthritis, faces cheaper competition, reports Reuters.

The offer to pay $280 per share, following weeks of exclusive talks, was unanimously approved by the boards of directors of both companies.

Johnson building is shown in Irvine, California

 

The deal represents a 23 percent premium to Actelion’s closing price on Wednesday and is more than 80 percent above the Nov. 23 closing price before reports emerged that Europe’s biggest biotech company had attracted takeover interest. Actelion shares jumped 20 percent to 273.30 francs by 1350 GMT as investors welcomed the deal.

“The structure is very attractive,” said Eleanor Taylor Jolidon, a fund manager at Union Bancaire Privee in Geneva, a top-40 Actelion investor.

The price vindicates the strategy of cardiologist Jean-Paul Clozel, who co-founded the company with his pediatrician wife Martine and friends in 1997, and has fended off bids over the years in the belief he could increase Actelion’s value by keeping it independent.

“The price is quite high at around 30 times price to estimated 2018 earnings. J&J is paying a lot and R&D is not even included, just a substantial minority stake,” one Zurich-based trader said.

“But it represents only 10 percent of (J&J’s) market capitalization and they are finally investing the cash they hold in Europe.”

Jefferies analysts said they did not expect any counterbids or competition concerns, while Berenberg analysts called it “a fantastic deal for Actelion and its shareholders” given concerns about the long-term growth prospects for its main products.

Actelion has been the subject of takeover speculation for weeks after J&J launched and then halted discussions with the Swiss company. French drugmaker Sanofi had also been interested, sources said, but was sidelined after J&J returned and began exclusive negotiations in December. Sanofi’s failure to come away with a big deal for a second time has added to pressure on its management.

Clozel said the J&J offer — putting Actelion’s established drugs into its bigger commercial organization while leaving riskier early-stage R&D assets in the new 600-employee company for Clozel to develop — convinced him this was the right one.

“With this structure it was not difficult,” he told Reuters after a news conference. “It’s always emotional but it’s not difficult. Because frankly it’s a good solution for everybody.”

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Advertisement

News of the Month

January 2017
S M T W T F S
« Dec   Feb »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: